Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases.

Recs

0
Player Avatar FoolBeater (30.31) Submitted: 3/13/2010 7:24:08 PM : Outperform Start Price: $5.28 PGNX Score: +45.43

Lord knows

Featured Broker Partners


Advertisement